Fair 23°
Tag:

AstraZeneca

News
COVID-19: New Study Reveals How Prevalent Blood Clots Are With Pfizer, Moderna Vaccines COVID-19: New Study Reveals How Prevalent Blood Clots Are With Pfizer, Moderna Vaccines
Covid-19: New Study Reveals How Prevalent Blood Clots Are With Pfizer, Moderna Vaccines The ratio of people who have suffered from blood clots after receiving the Moderna or Pfizer COVID-19 vaccine is approximately the same as those who receive the AstraZeneca vaccine, according to a new study. Oxford University researchers found that the number of people who receive blood clots after getting vaccinated is approximately the same for all three vaccines, with four in one million people experiencing cerebral venous thrombosis (CVT) after getting the Pfizer or Moderna vaccine, compared to five in one million people for the AstraZeneca vaccine. The new study comes in the wake of A…

SHARE

by Zak Failla
News
COVID-19: Pfizer Boasts Vaccine Candidate That's More Than 90% Effective COVID-19: Pfizer Boasts Vaccine Candidate That's More Than 90% Effective
Covid-19: Pfizer Boasts Vaccine Candidate That's More Than 90% Effective More reliable than the flu shot? Pfizer on Monday trumpeted a COVID-19 vaccine candidate as more than 90% effective – nearly three times better than the effectiveness of last season’s influenza vaccine. Pfizer said it hopes to have 50 million doses of the free vaccine ready by the end of this year and as many as 1.3 billion doses available next year to fight the deadly global pandemic. Two doses per person of BNT162b2 would be necessary, said the Manhattan-based drug maker, which teamed up with BioNTech of Germany to develop the booster. Pfizer plans to ask the federal Food and Drug Admini…

SHARE

by Jerry DeMarco
News
J&J: Mystery Illness Pauses Largest COVID Vaccine Trial J&J: Mystery Illness Pauses Largest COVID Vaccine Trial
J&J: Mystery Illness Pauses Largest COVID Vaccine Trial A mystery illness suffered by a participant has put the largest COVID-19 vaccine trial on hold, drug maker Johnson & Johnson announced. The New Jersey-based company – which sought 60,000 volunteers mostly over 60 – didn’t describe the illness or identify the patient in any way. “We must respect this participant's privacy,” J&J said in a statement. “We're also learning more about this participant's illness, and it's important to have all the facts before we share additional information.” J&J said it would provide transparent updates throughout the development of the randomized, …

SHARE

by Jerry DeMarco